Can-Fite BioPharma (CANF)

• Market cap: $10.7M
• 1 day: 6.06%
• 5 days: 15.89%
• 1 month: 12.18%
• 3 months: 31.58%
• 6 months: -18.60%
• Year to date: -2.23%
• 1 year: -20.09%
• 5 years: -86.54%
• 10 years: -99.75%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Employees: 5

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

8% more funds holding

Funds holding: 12 [Q3] → 13 (+1) [Q4]

0.03% less ownership

Funds ownership: 0.04% [Q3] → 0% (-0.03%) [Q4]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

88% less capital invested

Capital invested by funds: $1.52M [Q3] → $186K (-$1.33M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $10 471% upside
• Avg. target: $10 471% upside
• High target: $10 471% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 27% 1-year accuracy 77 / 282 met price target

471% upside $10

Buy Maintained

3 Mar 2025